In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients

Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters

doi:10.1128/AAC.04123-14

In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients

Antimicrob Agents Chemother. 2015 Jan;59(1):711-3. doi: 10.1128/AAC.04123-14. Epub 2014 Oct 27.

Authors

Anina Ratjen¹, Yvonne Yau², Jillian Wettlaufer¹, Larissa Matukas³, James E A Zlosnik⁴, David P Speert⁴, John J LiPuma⁵, Elizabeth Tullis⁶, Valerie Waters⁷

Affiliations

¹ Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
² Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
³ Division of Microbiology, Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Infectious Diseases, Department of Pediatrics, Centre for Understanding and Preventing Infection in Children, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
⁶ Division of Respirology and Keenan Research Centre of Li Ka Shing Knowledge Institute, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
⁷ Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada valerie.waters@sickkids.ca.

Abstract

Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Biofilms / drug effects
Burkholderia Infections / drug therapy
Burkholderia Infections / etiology
Burkholderia Infections / microbiology
Burkholderia cepacia complex / drug effects*
Cystic Fibrosis / complications
Cystic Fibrosis / microbiology*
Gram-Negative Bacterial Infections / drug therapy
Gram-Negative Bacterial Infections / etiology
Gram-Negative Bacterial Infections / microbiology
Humans
Microbial Sensitivity Tests
Stenotrophomonas maltophilia / drug effects*
Tobramycin / pharmacology
Tobramycin / therapeutic use*

Substances

Anti-Bacterial Agents
Tobramycin